[Skip to Content]
[Skip to Content Landing]
June 21, 1965


JAMA. 1965;192(12):15-17. doi:10.1001/jama.1965.03080250095045

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Testimony on Drug Patents.—  The Pharmaceutical Manufacturers Association told Congress a proposal to give the federal government patent rights to drugs developed in whole or in part with government funds would destroy incentive in the industry and control the marketing and development of new drugs.PMA President Austin Smith, MD, declared:"We all agree that regardless of the source of an invention the public should have the benefit of that invention. Let us not delude ourselves, however, that dedication of patents to the public accomplishes this objective. Merely making a drug invention does not cure anyone of any disease. The marketing of an invention does. Before the results of an invention are available, risk investments must be made in clinical tests, obtaining an effective new drug application, and marketing. These investments may run into millions of dollars. It is industry—not government—that must be relied upon to make this investment. The

First Page Preview View Large
First page PDF preview
First page PDF preview